Chronic naltrexone treatment increases expression of preproenkephalin preprotachykinin mRNA in discrete brain regions

Ann Tempel, John A. Kessler, R. Suzanne Zukin

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Long-term blockade of brain opioid receptors by the opiate antagonist naltrexone increases methionine-enkephalin content in the striatum and nucleus accumbens (Tempel et al., 1984). To determine whether these changes in peptide levels reflect increased peptide synthesis, we examined preproenkephalin mRNA content in discrete brain regions of control (placebo-treated) and chronic naltrexone-treated animals by Northern analysis. Chronic naltrexone treatment (8 d) led to an approximately 12-fold increase in the striatal content of preproenkephalin mRNA relative to that of control animals. In contrast, no statistically significant change was observed in striatal mRNA for cyclophilin (1B15) or actin. Small increases in preproenkephalin mRNA content occurred in the hippocampus (+40%) and hypothalamus (+19%). No significant changes occurred in the frontal cortex. Increases in levels of the mRNA were seen as early as 24 hr after antagonist treatment. In contrast, changes in opioid receptor density required 3-4 d to reach half-maximal up-regulation after chronic antagonist treatment. Recent evidence has suggested that substance P is regulated by opioid peptides. To determine whether substance P synthesis is altered by chronic antagonist treatment, the mRNA corresponding to the precursor for substance P was examined using a probe for exon-7 of the preprotachykinin gene. Preprotachykinin mRNA content in the striatum was increased 6-fold after chronic antagonist treatment relative to that of control animals. Substance P content was increased 3-fold after chronic antagonist treatment. These data suggest that chronic blockade of brain opioid receptors leads to the increased synthesis of both enkephalin and substance P in the striatum and that these changes are relatively specific. The finding of opiate antagonist-induced increases in preprotachykinin mRNA and substance P levels supports the concept of a role for enkephalin in the regulation of substance P gene expression.

Original languageEnglish (US)
Pages (from-to)741-747
Number of pages7
JournalJournal of Neuroscience
Volume10
Issue number3
StatePublished - 1990

Fingerprint

Naltrexone
Substance P
Messenger RNA
Brain
Opiate Alkaloids
Corpus Striatum
Enkephalins
Opioid Receptors
Therapeutics
Cyclophilins
Methionine Enkephalin
Peptides
Opioid Peptides
Narcotic Antagonists
preproenkephalin
preprotachykinin
Nucleus Accumbens
Frontal Lobe
Hypothalamus
Actins

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Chronic naltrexone treatment increases expression of preproenkephalin preprotachykinin mRNA in discrete brain regions. / Tempel, Ann; Kessler, John A.; Zukin, R. Suzanne.

In: Journal of Neuroscience, Vol. 10, No. 3, 1990, p. 741-747.

Research output: Contribution to journalArticle

@article{1b52f00804fe4589a5866862ea672bd2,
title = "Chronic naltrexone treatment increases expression of preproenkephalin preprotachykinin mRNA in discrete brain regions",
abstract = "Long-term blockade of brain opioid receptors by the opiate antagonist naltrexone increases methionine-enkephalin content in the striatum and nucleus accumbens (Tempel et al., 1984). To determine whether these changes in peptide levels reflect increased peptide synthesis, we examined preproenkephalin mRNA content in discrete brain regions of control (placebo-treated) and chronic naltrexone-treated animals by Northern analysis. Chronic naltrexone treatment (8 d) led to an approximately 12-fold increase in the striatal content of preproenkephalin mRNA relative to that of control animals. In contrast, no statistically significant change was observed in striatal mRNA for cyclophilin (1B15) or actin. Small increases in preproenkephalin mRNA content occurred in the hippocampus (+40{\%}) and hypothalamus (+19{\%}). No significant changes occurred in the frontal cortex. Increases in levels of the mRNA were seen as early as 24 hr after antagonist treatment. In contrast, changes in opioid receptor density required 3-4 d to reach half-maximal up-regulation after chronic antagonist treatment. Recent evidence has suggested that substance P is regulated by opioid peptides. To determine whether substance P synthesis is altered by chronic antagonist treatment, the mRNA corresponding to the precursor for substance P was examined using a probe for exon-7 of the preprotachykinin gene. Preprotachykinin mRNA content in the striatum was increased 6-fold after chronic antagonist treatment relative to that of control animals. Substance P content was increased 3-fold after chronic antagonist treatment. These data suggest that chronic blockade of brain opioid receptors leads to the increased synthesis of both enkephalin and substance P in the striatum and that these changes are relatively specific. The finding of opiate antagonist-induced increases in preprotachykinin mRNA and substance P levels supports the concept of a role for enkephalin in the regulation of substance P gene expression.",
author = "Ann Tempel and Kessler, {John A.} and Zukin, {R. Suzanne}",
year = "1990",
language = "English (US)",
volume = "10",
pages = "741--747",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "3",

}

TY - JOUR

T1 - Chronic naltrexone treatment increases expression of preproenkephalin preprotachykinin mRNA in discrete brain regions

AU - Tempel, Ann

AU - Kessler, John A.

AU - Zukin, R. Suzanne

PY - 1990

Y1 - 1990

N2 - Long-term blockade of brain opioid receptors by the opiate antagonist naltrexone increases methionine-enkephalin content in the striatum and nucleus accumbens (Tempel et al., 1984). To determine whether these changes in peptide levels reflect increased peptide synthesis, we examined preproenkephalin mRNA content in discrete brain regions of control (placebo-treated) and chronic naltrexone-treated animals by Northern analysis. Chronic naltrexone treatment (8 d) led to an approximately 12-fold increase in the striatal content of preproenkephalin mRNA relative to that of control animals. In contrast, no statistically significant change was observed in striatal mRNA for cyclophilin (1B15) or actin. Small increases in preproenkephalin mRNA content occurred in the hippocampus (+40%) and hypothalamus (+19%). No significant changes occurred in the frontal cortex. Increases in levels of the mRNA were seen as early as 24 hr after antagonist treatment. In contrast, changes in opioid receptor density required 3-4 d to reach half-maximal up-regulation after chronic antagonist treatment. Recent evidence has suggested that substance P is regulated by opioid peptides. To determine whether substance P synthesis is altered by chronic antagonist treatment, the mRNA corresponding to the precursor for substance P was examined using a probe for exon-7 of the preprotachykinin gene. Preprotachykinin mRNA content in the striatum was increased 6-fold after chronic antagonist treatment relative to that of control animals. Substance P content was increased 3-fold after chronic antagonist treatment. These data suggest that chronic blockade of brain opioid receptors leads to the increased synthesis of both enkephalin and substance P in the striatum and that these changes are relatively specific. The finding of opiate antagonist-induced increases in preprotachykinin mRNA and substance P levels supports the concept of a role for enkephalin in the regulation of substance P gene expression.

AB - Long-term blockade of brain opioid receptors by the opiate antagonist naltrexone increases methionine-enkephalin content in the striatum and nucleus accumbens (Tempel et al., 1984). To determine whether these changes in peptide levels reflect increased peptide synthesis, we examined preproenkephalin mRNA content in discrete brain regions of control (placebo-treated) and chronic naltrexone-treated animals by Northern analysis. Chronic naltrexone treatment (8 d) led to an approximately 12-fold increase in the striatal content of preproenkephalin mRNA relative to that of control animals. In contrast, no statistically significant change was observed in striatal mRNA for cyclophilin (1B15) or actin. Small increases in preproenkephalin mRNA content occurred in the hippocampus (+40%) and hypothalamus (+19%). No significant changes occurred in the frontal cortex. Increases in levels of the mRNA were seen as early as 24 hr after antagonist treatment. In contrast, changes in opioid receptor density required 3-4 d to reach half-maximal up-regulation after chronic antagonist treatment. Recent evidence has suggested that substance P is regulated by opioid peptides. To determine whether substance P synthesis is altered by chronic antagonist treatment, the mRNA corresponding to the precursor for substance P was examined using a probe for exon-7 of the preprotachykinin gene. Preprotachykinin mRNA content in the striatum was increased 6-fold after chronic antagonist treatment relative to that of control animals. Substance P content was increased 3-fold after chronic antagonist treatment. These data suggest that chronic blockade of brain opioid receptors leads to the increased synthesis of both enkephalin and substance P in the striatum and that these changes are relatively specific. The finding of opiate antagonist-induced increases in preprotachykinin mRNA and substance P levels supports the concept of a role for enkephalin in the regulation of substance P gene expression.

UR - http://www.scopus.com/inward/record.url?scp=0025234429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025234429&partnerID=8YFLogxK

M3 - Article

C2 - 2319301

AN - SCOPUS:0025234429

VL - 10

SP - 741

EP - 747

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 3

ER -